Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Cabergoline

Plain-language summaryIntrigue 56 / 100

Cabergoline, sold as Dostinex, is a long-acting ergot dopamine agonist with a half-life measured in days rather than hours, allowing once or twice weekly dosing. It is the first-line drug for prolactinomas (pituitary tumors that secrete the hormone prolactin), where it normalizes hormone levels and shrinks tumors in most patients. The principal safety concern is heart valve damage from chronic 5-HT2B receptor activation, which has been documented at high cumulative doses used in Parkinson disease. At the lower doses used for prolactinomas the valve risk appears small but is not zero, and patients on long-term therapy receive periodic echocardiograms. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

48/100

Gold-standard prolactinoma agent with settled mechanism and limited frontier research appeal

Look, cabergoline is one of those compounds where the clinical story is essentially settled and the research frontier has moved on. FDA approved in 1996, it displaced bromocriptine as the first-line agent for hyperprolactinemia and prolactinoma on every metric that matters: efficacy, tolerability, dosing convenience from that 60-to-100-hour half-life, and a cleaner receptor selectivity profile. Within its approved indication, cabergoline is about as clear a category winner as you’ll find in endocrinology. Thats where the differentiation score comes from.

The problem, from a research library standpoint, is that the interesting questions have already been answered. D2 receptor agonism is thoroughly understood pharmacology. The prolactin-lowering mechanism is textbook. The 5-HT2B partial agonism and its valvulopathy risk at Parkinson-range cumulative doses is documented, quantified, and clinically contextualized. There is no mechanistic mystery here, no new receptor biology to untangle, no signal that tells a serious investigator something genuinely new is waiting.

The off-label angles that occasionally surface — cocaine dependence, reward-circuit modulation, sexual function — have been explored in small studies for years without producing compelling, replicated human signal. We think the cocaine dependence rationale is actually sound: D2 receptor downregulation is a real feature of stimulant use disorder, and restoring D2 tone with a clean long-acting agonist is a plausible pharmacological intervention. But the clinical trial record has been modest and inconsistent across groups, and that keeps the translational score honest even for that angle.

What we genuinely like about cabergoline for bench work is its utility as the canonical long-acting D2 reference agonist. If your research program touches dopamine receptor dynamics, prolactin as a neuroendocrine readout, or D2-mediated feedback loops in reward or reproductive biology, cabergoline is a clean, well-characterized probe. Oral bioavailability is solid, half-life is predictable, and D2 selectivity over non-dopaminergic receptors is meaningfully better than bromocriptine. For those specific programs, it earns its place on the shelf.

Honestly, thats about as far as the excitement goes. Cabergoline has been used clinically for three decades and the evidence base reflects that maturity — but maturity cuts both ways. Well-replicated findings in a settled indication don’t move the frontier. For labs working directly on prolactin biology or D2 receptor pharmacology, it’s a genuinely valuable reference tool. For most other research programs, the literature is closed and there isn’t much discovery space left.

Novelty

22

Mechanism promise

30

In-category differentiation

58

Evidence quality

68

Translational signal

72

Research bench value

48

Rationale Cabergoline scores high on differentiation and translational signal because it is definitively best-in-class for its approved indication, but novelty and mechanism scores drag the overall down hard — it’s a 30-year-old single-receptor ergoline with no meaningful mechanistic surprises and a research conversation that’s largely closed. The off-label angles (cocaine dependence, reward modulation) have produced modest, inconsistent human data that don’t rescue the novelty picture.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long-acting ergoline D2 dopamine agonist

A long-acting ergoline D2 dopamine receptor agonist; first-line for prolactinoma and used off-label for Parkinson disease maintenance.

Abstract

Cabergoline ((6aR,9R,10aS)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-7-(2-propenyl)-ergoline-8-beta-carboxamide; CAS 81409-90-7; molecular formula C26H37N5O2; molecular weight 451.61) is a long-acting ergoline D2 dopamine receptor agonist developed at Pharmacia and approved by the FDA in 1996 under the trade name Dostinex. The compound has high D2 affinity (Ki approximately 0.6 nM) with minimal activity at non-dopaminergic receptors compared to bromocriptine. Plasma half-life is approximately 60 to 100 hours, the longest of any clinical dopamine agonist, supporting twice-weekly oral dosing. Approved for hyperprolactinemia (prolactinoma, idiopathic hyperprolactinemia). Off-label use in Parkinson disease (less common since the introduction of non-ergot agonists), cocaine dependence, and dopamine-deficiency syndromes. The 5-HT2B partial agonism produces a recognized but rare risk of cardiac valvulopathy at high cumulative doses (Parkinson dose ranges); the lower prolactinoma doses are not associated with this risk. Used as the canonical long-acting ergoline dopamine agonist.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-318Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Buprenorphine

Plain-language summaryIntrigue 76 / 100

Buprenorphine is a semi-synthetic opioid with an unusual receptor profile that has made it the cornerstone of medication-assisted treatment for opioid use disorder. As a high-affinity partial mu-opioid agonist it activates the receptor enough to suppress withdrawal and craving but with a built-in ceiling on respiratory depression that makes overdose much less likely than with full agonists. Its kappa antagonism may contribute to mood benefit. The combination with naloxone (Suboxone) discourages injection abuse because naloxone is not orally active but blocks opioid effects if injected. Approved for OUD in the US in 2002, it has saved many lives. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

57/100

Mature Schedule III MAT agent with a genuinely interesting KOR antagonism angle but limited frontier research appeal

Look, buprenorphine is one of the most clinically important opioid-system compounds ever developed, and that’s precisely why it scores where it does here. The evidence base for OUD treatment is enormous: multiple FDA approvals, decades of real-world data, a well-characterized safety margin built on mu partial agonism. But clinically essential and interesting research target right now are two different questions, and this rubric is asking the second one.

The pharmacology is genuinely interesting. What buprenorphine does is unusual: high-affinity mu binding (Ki approximately 0.2 nM) with roughly 30 percent intrinsic activity, which produces analgesia and craving suppression without the respiratory depression ceiling you get from full agonists. And then layered on top, concurrent kappa-opioid antagonism and ORL1 partial agonism. That’s a legitimately complex pharmacological profile. The KOR antagonism is the angle that keeps serious investigators paying attention. KOR activation is strongly implicated in dysphoria and stress-driven depression, so blocking it while partially activating mu has real mechanistic rationale as an antidepressant approach. Some early clinical data support this, though effect sizes are modest and the literature is still maturing.

Here’s the problem with using buprenorphine as the probe for that question: the mu signal is always in the room. Selective KOR antagonists like aticapant or navacaprant give you cleaner experimental handles on the kappa axis in isolation. With buprenorphine, any behavioral or molecular readout you get in a model is a convolution of at least three receptor activities. Thats not fatal for all research designs, but it limits interpretability in a way that matters for mechanistic work.

From a bench value standpoint, it remains a useful reference tool. If your program involves opioid receptor partial agonism dynamics, tolerance and ceiling-effect modeling, or mu/kappa crosstalk, buprenorphine is the canonical standard. We credit that. The Schedule III status creates meaningful practical friction for investigators who aren’t already operating in a controlled-substance-licensed environment, which is worth acknowledging honestly.

What we don’t see is a strong case for building a new research program around buprenorphine in 2025 unless that program is specifically about OUD pharmacotherapy refinement, KOR biology in mood disorders where selectivity constraints are acceptable, or receptor pharmacology where a mu partial agonist reference is genuinely needed. Important compound, belongs in the library, but isnt where the frontier is.

Novelty

22

Mechanism promise

60

In-category differentiation

58

Evidence quality

78

Translational signal

72

Research bench value

65

Rationale Buprenorphine’s clinical evidence base for OUD is massive but that’s not what drives research scores; novelty is low given a 1981 approval and decades of trodden literature. The kappa-opioid antagonism angle for treatment-resistant depression is the one live research thread, but it’s mechanistically muddied by concurrent mu partial agonism, and cleaner selective KOR antagonists exist as investigational probes. Schedule III cap of 75 does not bind since the calculated score falls below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid partial agonist + kappa-opioid antagonist

A semi-synthetic mu-opioid partial agonist with kappa-opioid antagonism; the primary medication-assisted treatment for opioid use disorder.

Abstract

Buprenorphine ((2S,6R,7R,14S)-17-cyclopropylmethyl-7-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-4,5-epoxy-6,14-ethano-morphinan-3-ol; CAS 52485-79-7; molecular formula C29H41NO4; molecular weight 467.65) is a semi-synthetic thebaine-derived mu-opioid partial agonist with concurrent kappa-opioid antagonist and ORL1 (nociceptin receptor) partial agonist activity. Originally approved by the FDA in 1981 as an analgesic; reformulated and approved in 2002 (Subutex, Suboxone) for opioid use disorder. Mu-opioid affinity is high (Ki approximately 0.2 nM) with intrinsic activity approximately 30 percent (partial agonism); the partial agonism produces a ceiling effect on respiratory depression and euphoria, distinguishing buprenorphine safety profile from full agonists like fentanyl or morphine. Long plasma half-life (24 to 60 hours) supports once-daily or less-frequent dosing. Suboxone formulation includes naloxone (a mu antagonist with poor sublingual bioavailability) to deter intravenous misuse. Approved for opioid use disorder and chronic pain (transdermal Butrans). The kappa-opioid antagonism is being investigated for treatment-resistant depression. Used as the canonical mu-opioid partial agonist in addiction medicine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-350Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Synephrine

Plain-language summaryIntrigue 42 / 100

Synephrine is an alkaloid from bitter orange peel (Citrus aurantium) that became a bestselling thermogenic supplement after the FDA banned ephedra in 2004. Structurally it resembles phenylephrine, but it preferentially activates beta-3 adrenergic receptors over the alpha-1 and beta-1 receptors that drive blood pressure changes. The beta-3 activity stimulates fat oxidation and thermogenesis in adipose tissue, which is the basis of the weight-loss claims. Clinical evidence for actual fat loss is modest at best. Plasma half-life is about two hours. Used as a beta-3-preferring adrenergic agonist in metabolic research and as the workhorse stimulant ingredient in many over-the-counter weight-loss formulas. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

27/100

Outcompeted beta-3 agonist with modest evidence, useful only as a reference standard

Look, synephrine got its moment in the sun after the 2004 ephedra ban, and that moment is over. It’s a phenylethanolamine alkaloid from bitter orange with a preference for beta-3 adrenergic receptors over the alpha-1 and beta-1 activity that got ephedra pulled in the first place. That selectivity profile was genuinely interesting in the supplement context circa 2005. In 2026, it’s a textbook example of a compound the research frontier has lapped.

The mechanism isn’t wrong. Beta-3 adrenergic receptors are real targets expressed in adipose tissue and other metabolic compartments, and agonism there does drive thermogenesis via cAMP-mediated lipolysis. The problem is synephrine does this modestly, and we now have far better tools for studying this receptor system. Mirabegron, a pharmaceutical-grade selective beta-3 agonist with solid PK data and actual receptor selectivity characterization, is the obvious bench choice for any serious beta-3 adrenergic research program. Synephrine’s selectivity is partial at best, its potency is low, and the signal-to-noise ratio for controlled experiments is poor compared to purpose-built probes.

The clinical literature reflects exactly this. Multiple small trials have looked at synephrine for thermogenesis and body weight endpoints. The honest read: effect sizes are small, the data isnt compelling by any rigorous standard, and no serious phase 2 or 3 program is chasing it. The broader adrenergic and metabolic pharmacology space has moved to GLP-1 biology, beta-3 selective drugs with actual selectivity data, and mitochondrial targets with novel mechanisms. Synephrine is watching from the parking lot.

What we don’t like about it as a research compound is the ceiling problem. Even a clean, well-powered synephrine study in 2026 just confirms what’s already known about a mechanism that’s already been characterized in depth. The evidence base is decent by supplement standards (multiple small clinical studies, some methodological replication), but that bar is low and the information value per experiment is low. A landmark paper is not coming out of this compound.

The only scenario where it earns bench time today is narrow: comparative pharmacology where you need a weak beta-3 agonist as a reference alongside something more interesting, or structure-activity work in the phenylethanolamine chemical series. That’s a limited application, and most programs would reach for mirabegron or a custom ligand instead. We score it where it belongs: well-understood, outcompeted, modest evidence, and limited utility for anything a frontier investigator would care about right now.

Novelty

20

Mechanism promise

28

In-category differentiation

22

Evidence quality

38

Translational signal

32

Research bench value

25

Rationale Synephrine’s beta-3 adrenergic selectivity was genuinely interesting post-ephedra but is now thoroughly characterized and outcompeted by purpose-built pharmaceutical probes like mirabegron; clinical evidence exists but effect sizes are small, replication is weak by serious trial standards, and the information yield per experiment is too low for anything on the current research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Adrenergic agonist (bitter orange alkaloid)

p-Synephrine; a phenylethanolamine alkaloid from Citrus aurantium (bitter orange); a beta-3 adrenergic-preferring agonist used as a thermogenic supplement.

Abstract

Synephrine (p-synephrine, (R/S)-4-[1-hydroxy-2-(methylamino)ethyl]phenol; CAS 94-07-5; molecular formula C9H13NO2; molecular weight 167.21) is a phenylethanolamine alkaloid from Citrus aurantium (bitter orange) and other Citrus species. The compound is a structural analog of phenylephrine (the m-isomer) with a beta-3 adrenergic preference (relative to alpha-1 and beta-1) that distinguishes its pharmacology. The beta-3 activity drives thermogenesis and fat oxidation in adipose tissue, the basis for its supplement use as a weight-loss aid. Synephrine became prominent after the 2004 FDA ban on ephedra (which contained the more potent ephedrine). Clinical evidence for weight-loss effect is modest. Plasma half-life is approximately 2 hours. Used as a beta-3-preferring adrenergic agonist in metabolic research and supplement formulations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-383Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
HMB (β-Hydroxy-β-methylbutyrate)

Our opinion on this compoundEstablished workhorse

37/100

Mature anti-catabolic metabolite with real catabolic-state signal but low novelty as a research target

Look, HMB has been around since the early 1990s, and the core story hasn’t changed much. It’s a metabolite of leucine, produced via alpha-ketoisocaproate during roughly 5% of leucine catabolism, and the proposed mechanism is straightforward: reduce protein breakdown through ubiquitin-proteasome pathway inhibition while nudging mTOR signaling upward. Thats a real mechanism. Just not a particularly exciting one. We’ve known how the proteasome works for decades, and HMB’s interaction with it is well-characterized to the point of being textbook.

The evidence picture is better than you’d expect from something marketed this aggressively. In catabolic states, the signal is genuine. HIV wasting trials, cancer cachexia cohorts, bedrest-induced atrophy protocols, and post-surgical recovery studies all show meaningful lean mass preservation at 3 g/day. The Vukovich group, Flakoll et al., and several independent labs replicated this in sarcopenic and hospitalized populations. That is the compound at its best. In healthy resistance-trained athletes, the effect size compresses fast. The meta-analyses in athletic populations are messy, and the dramatic early claims from Wilson et al. didn’t survive independent replication at scale.

The free acid form (HMB-FA) has better pharmacokinetics than the calcium salt, faster absorption and higher peak plasma concentration. Interesting story in theory. But most of the foundational clinical work used Ca-HMB, so the HMB-FA literature is thinner, and the practical effect-size advantage looks modest when you read the head-to-head data carefully. Not a reason to deprioritize the compound, but not a reason to get excited either.

What we don’t like about HMB as a research target: the mechanism doesn’t point at anything that isn’t already well-mapped. If you’re trying to understand proteasome biology, you’re reaching for more specific chemical probes. If you’re trying to build an anti-catabolic protocol, you’re comparing HMB to leucine supplementation, essential amino acid formulations, and the newer mitochondrial peptide work, and HMB doesn’t come out ahead on bench utility. The probe value is real but narrow. It works best as a comparator arm in muscle-wasting trial design. That’s about its ceiling.

For investigators in catabolic biology, it earns a place as a reference compound: well-sourced, defined pharmacokinetics, clean mechanism. For anyone focused on the frontier of muscle-sparing or anti-aging research, the interesting signals are coming from myostatin pathway modulators, mitochondrial peptides, and GLP-1 adjacent compounds. HMB is the baseline you measure against, not the signal you’re chasing. Honest assessment: score this one and move on.

Novelty

22

Mechanism promise

28

In-category differentiation

35

Evidence quality

52

Translational signal

52

Research bench value

40

Rationale HMB lands just under the foundational-metabolite ceiling on its own calculated merit: the catabolic-state evidence base is genuine and multi-lab replicated, but the mechanism is unremarkable, novelty is low, and differentiation from leucine itself or EAA protocols is modest. No cap binds because the axes score it there naturally.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Leucine metabolite (anti-catabolic supplement)

Beta-hydroxy-beta-methylbutyrate; a leucine metabolite that reduces muscle protein breakdown; used in catabolic states and as a supplement.

Abstract

HMB (beta-hydroxy-beta-methylbutyric acid; CAS 625-08-1; molecular formula C5H10O3; molecular weight 118.13; Ca-HMB salt CAS 135236-72-5) is a metabolite of the branched-chain amino acid leucine, produced by approximately 5 percent of leucine catabolism via alpha-ketoisocaproate. Mechanism: HMB reduces muscle protein breakdown via inhibition of the ubiquitin-proteasome pathway and enhanced cell membrane integrity; secondary effects on muscle protein synthesis through mTOR pathway activation. The clinical evidence is strongest in catabolic states (HIV wasting, cancer cachexia, sarcopenia of aging, bedrest, post-surgical recovery) where 3 g/day reduces protein breakdown and preserves lean mass. In healthy resistance-trained athletes, the effect is small. The free acid form (HMB-FA) has improved pharmacokinetics over the calcium salt (Ca-HMB) but most research uses Ca-HMB. Plasma half-life is approximately 2 hours. Used as a reference anti-catabolic supplement.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-399Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Farampator (CX-691)

Plain-language summaryIntrigue 42 / 100

Farampator (CX-691) is a methylsulfonamide AMPA potentiator. Phase 2 trials in cognitive impairment and depression showed modest signals. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

47/100

Phase 2 ampakine with an interesting rapid-antidepressant signal that ultimately fizzled out before delivering clear clinical proof

Look, farampator is one of those compounds where the mechanism story is genuinely compelling and the clinical history is genuinely disappointing. It’s a methylsulfonamide AMPA positive allosteric modulator from the Cortex Pharmaceuticals CX-series, licensed through Organon and Schering-Plough before Merck killed the program after acquisition. That corporate graveyard timeline tells you something before you even read the trial results.

The mechanism is the most interesting thing here. AMPA PAMs potentiate fast glutamatergic transmission, augmenting AMPA receptor-mediated currents without direct agonism, and the hypothesis connecting that to rapid antidepressant effects is actually well-reasoned. The dominant theory for ketamine’s rapid antidepressant action leans heavily on downstream AMPA receptor potentiation: NMDA blockade disinhibits AMPA throughput, which drives BDNF release and rapid synaptic strengthening. If thats the key step, then a direct AMPA PAM should shortcut the whole thing. Farampator reached Phase 2 in MDD and produced rapid antidepressant-like effects that reportedly resembled ketamine’s time course. That’s a real data point, and it’s not nothing.

What we don’t like is the overall trajectory. The CX-series ampakines have been promising rapid cognitive and mood tools since the late 1990s, and none of them delivered a clean clinical win. CX-516, the first-generation compound, was weaker. CX-717 was pushed through DARPA-funded sleep deprivation work and also didnt breakthrough. Farampator sits in the middle of that lineage, with intermediate pharmacokinetics and intermediate results. Mixed Phase 2 readouts across MDD, Alzheimer disease, and ADHD is a pattern, not a fluke. Merck walked away, and there’s been no serious revival since.

As a research tool, farampator has real utility specifically for investigators studying the AMPA-centered rapid antidepressant mechanism. If you’re trying to dissect whether AMPA potentiation per se drives the rapid mood effect, or whether you need the upstream NMDA block, farampator lets you probe that question in ways that most competitors don’t. It’s one of a small number of AMPA PAMs with actual Phase 2 human PK and PD data attached, which makes the compound more useful as a translational reference point than the purely preclinical alternatives.

Sourcing is limited and quality verification matters more here than for mainstream compounds. The literature is diffuse, the Phase 2 data hasn’t been fully published in accessible form, and bench investigators should account for that. We think the compound belongs in a serious nootropic or rapid antidepressant research program as a mechanistic probe, not as a lead compound. Interesting enough to have on the shelf; not interesting enough to center a research agenda on.

Novelty

35

Mechanism promise

62

In-category differentiation

45

Evidence quality

50

Translational signal

42

Research bench value

50

Rationale Farampator earns credit for genuine Phase 2 clinical exposure across three indications and for sitting at an intellectually interesting intersection of AMPA potentiation and rapid antidepressant pharmacology, but the development program was discontinued with mixed results, the ampakine class has accumulated two decades of mostly inconclusive clinical output, and the compound itself is not especially novel. Its main research value today is as a probe for the AMPA-mediated synaptic potentiation hypothesis of rapid antidepressant action.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylsulfonamide AMPA potentiator

An Organon/Schering-Plough ampakine (CX-691) that reached Phase 2 in major depressive disorder and Alzheimer disease.

Abstract

Farampator (CX-691, ORG-24448; CAS 211735-76-1; molecular formula C16H22N2O3S; molecular weight 322.42) is a methylsulfonamide-class AMPA receptor positive allosteric modulator developed by Cortex Pharmaceuticals and licensed to Organon (subsequently Schering-Plough, then Merck). The compound advanced through Phase 2 trials in major depressive disorder, Alzheimer disease, and adult ADHD with mixed results; the development program was discontinued after the Schering-Plough acquisition by Merck. Mechanism is AMPA receptor positive allosteric modulation with characteristics intermediate between the early CX-516 class and the later sustained-action ampakines. Pharmacokinetics: plasma half-life approximately 5 to 6 hours; oral bioavailability adequate. The compound is sold as a research chemical with limited availability. The clinical evidence base in depression specifically is interesting: rapid antidepressant-like effects analogous to those seen with ketamine were observed in Phase 2, suggesting the ampakine mechanism may share some clinical pharmacology with NMDA-blocking rapid antidepressants.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-058Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Melanotan I (Afamelanotide)

Plain-language summaryIntrigue 70 / 100

Melanotan I (afamelanotide), sold as Scenesse, is a linear melanocortin receptor agonist approved for erythropoietic protoporphyria (a rare light-sensitivity disorder). It produces skin tanning by activating melanin synthesis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

FDA-approved EPP treatment with solid clinical evidence but a mature, well-characterized mechanism

Afamelanotide is one of the more unusual entries in any research library: it’s a drug with an approved indication, real phase 3 data, and a delivery mechanism (the subcutaneous implant) that you wont find anywhere else in peptide research. For erythropoietic protoporphyria the clinical case is settled. Patients tolerate meaningfully more light exposure without the painful phototoxic reactions that define the disease, and the effect size is clinically significant. That’s a real outcome, and we respect it.

The problem, from a research-merit standpoint, is that the mechanism is about as old as the peptide itself. The melanocortin system was being mapped in the 1980s when Mac Hadley’s group at Arizona synthesized this compound. MC1R drives melanin synthesis; MC4R handles appetite and sexual function; MC3R sits in between with roles in energy homeostasis and inflammation. Afamelanotide hits all four (MC1, MC3, MC4, MC5) non-selectively, with MC1 carrying most of the pharmacological weight in its approved indication. Thats not a novel mechanism. It’s well-characterized, multi-replicated, and the clinical approval closed most of the open questions about what the compound does in people.

We do think there’s a second story trying to emerge here. MC1R has anti-inflammatory signaling beyond its canonical pigmentation role, and some preclinical work has examined afamelanotide in contexts like solar UV-induced immunosuppression and cutaneous immune modulation. There’s a reasonable hypothesis that the photoprotective effect isn’t purely about melanin density but also involves MC1R-mediated modulation of Langerhans cell behavior and pro-inflammatory cytokine expression. Interesting. But multi-lab clinical evidence for those indications doesnt exist yet, and afamelanotide hasn’t broken out of the EPP box in terms of serious independent investigation.

On differentiation, afamelanotide occupies a clear position: it’s the approved linear analog, while Melanotan II (the cyclic analog) carries stronger MC4 agonism and all the associated appetite and sexual-function effects. If your research question is specifically MC1R-driven, afamelanotide is actually a cleaner probe than MT-II for reducing MC4 confounds. That’s worth something. The sustained-release implant formulation is also genuinely unique in peptide research and gives you pharmacokinetics that injection protocols simply cannot replicate for certain study designs.

The honest summary: afamelanotide has the best documentation of any melanocortin agonist in the library, but the questions it answers are mostly already answered. The live bench interest sits at the edges now, in the MC1R inflammation story and in EPP disease modeling. For investigators working specifically in those corners, it’s a solid tool. For general research programs, the novelty ceiling is real, and the score reflects that ceiling directly.

Novelty

30

Mechanism promise

38

In-category differentiation

55

Evidence quality

62

Translational signal

70

Research bench value

50

Rationale Scores as established-active: the EPP approval gives it real clinical evidence and a clear translational signal, but the melanocortin mechanism dates to the 1980s and most open questions are resolved. The only frontier angles are the MC1R anti-inflammatory story and EPP disease model work, which lift differentiation slightly but cannot rescue novelty above 30.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Alpha-MSH analog (linear heptadecapeptide)

A linear alpha-MSH analog approved as Scenesse for erythropoietic protoporphyria, characterized by sustained skin pigmentation.

Abstract

Melanotan I (Afamelanotide, Scenesse; (Nle4, D-Phe7)-alpha-MSH; CAS 75921-69-6; molecular formula C78H111N21O19; molecular weight 1646.85) is a linear heptadecapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) developed at the University of Arizona by Mac Hadley’s group in the 1980s. The compound was approved by the FDA in 2019 (and earlier in Europe) for erythropoietic protoporphyria, a rare genetic photosensitivity disorder. Mechanism is non-selective melanocortin receptor agonism (MC1, MC3, MC4, MC5); the MC1 activity drives melanin synthesis in melanocytes producing tan-like skin pigmentation. The clinical formulation is a 16 mg subcutaneous implant providing sustained release over 60 days. The compound is sold as a research chemical/peptide for sunless tanning applications, though regulatory authorities have issued warnings against this use. Pharmacokinetics: subcutaneous administration; the implant formulation provides 30 to 60 days of activity per dose.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-092Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bacopa monnieri

Plain-language summaryIntrigue 60 / 100

Bacopa monnieri is an Ayurvedic herb traditionally used for memory enhancement. The bacosides drive cholinergic and antioxidant effects. Effects build over weeks to months of consistent use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

Replicated clinical signal in elderly populations but mechanistically messy and not a frontier research target

Cap applied Common OTC herb/supplement: max 35

Look, Bacopa has something a lot of herbal nootropics dont: actual replicated clinical data. The Stough group at Swinburne, the Roodenrys trials, Morgan and Stevens — multiple independent labs have run real double-blind RCTs and found genuine effects on working memory and learning rate in older adults after 8 to 12 weeks of chronic dosing. We don’t dismiss that. But the question the rubric asks is whether a serious bench scientist should prioritize this compound right now, and the honest answer is: probably not.

The mechanism is the first problem. Bacopa is a complex saponin mixture — bacosides A, B, A3, and several others — with effects attributed to cholinergic facilitation, antioxidant activity, dendritic arborization, BDNF modulation, and several other pathways that overlap with nearly every other neuroprotective extract on the market. Thats not elegant pharmacology. Thats a shotgun. When you can’t isolate which constituent is driving the effect, designing a controlled experiment becomes difficult. Researchers who want to interrogate cholinergic memory mechanisms have cleaner tools. Researchers who want to model dendritic plasticity have more precise probes available.

The differentiation picture is similarly flat. In the cognitive enhancement extract space, Bacopa competes with lion’s mane (BDNF and NGF signaling), ashwagandha (HPA axis and cortisol dynamics), and a range of more precisely characterized synthetic compounds. Its strongest claim — working memory improvement in elderly subjects over 8 to 12 weeks — is real, but the effect sizes across the RCTs are modest, the slow onset window makes acute mechanistic studies hard to design cleanly, and the elderly-population signal doesn’t obviously generalize to younger or healthier subjects that many active research programs focus on.

Evidence quality is genuinely the strongest axis here, and we score it accordingly. Multiple independent labs, consistent directional findings, real double-blind designs. That’s better than most compounds in this category. But evidence of what, exactly? That a complex extract does something to memory in older adults doesn’t tell you which molecule, which pathway, or what’s worth targeting next. It closes questions rather than opening them.

For a library focused on novel targets and bench utility, Bacopa sits in a frustrating middle ground: too well-studied to be a frontier discovery, too poorly characterized mechanistically to serve as a sharp research probe. It earns its place as reference context for anyone working in cognitive enhancement or Ayurvedic extract pharmacology, but we think serious investigative resources belong on more tractable problems right now.

Novelty

22

Mechanism promise

28

In-category differentiation

35

Evidence quality

52

Translational signal

50

Research bench value

30

Rationale Bacopa earns real marks on evidence and translational signal (multiple independent RCTs with consistent directional effects on working memory in elderly subjects) but scores low on novelty, mechanism elegance, and bench probe value. The OTC herb cap of 35 binds precisely at the weighted calculation, reflecting a compound that is real but mature and not a priority for bench-scale investigation.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ayurvedic cognitive enhancement extract

A creeping aquatic plant extract standardized to bacosides (saponin glycosides) with documented working memory and learning enhancement in elderly populations.

Abstract

Bacopa monnieri (Brahmi) is a creeping aquatic plant used in Ayurvedic medicine for memory enhancement and longevity. The active constituents are bacosides (notably bacoside A, B, A3, and others), saponin glycosides standardized in commercial extracts at 20 to 55 percent total bacoside content. Multiple randomized trials in elderly subjects demonstrate working memory enhancement, learning rate improvement, and reduced anxiety with chronic dosing (8 to 12 weeks before full effect emerges). Mechanism is incompletely characterized but includes cholinergic facilitation, antioxidant activity, modulation of dendritic branching, and neuroprotective effects. The clinical effect requires sustained dosing; acute effects are minimal. Doses are typically 300 to 600 mg standardized extract per day for at least 8 to 12 weeks.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-109Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Davunetide (NAP)

Plain-language summaryIntrigue 65 / 100

Davunetide (NAP) is an 8-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP). It supports microtubule integrity in neurons. Phase 2/3 trials in progressive supranuclear palsy were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

Interesting ADNP-derived tau biology probe that failed its pivotal PSP trial but retains real bench utility

Look, the honest framing on davunetide is this: it had a serious shot, it swung, and it missed. Allon Therapeutics ran a genuine pivotal trial in progressive supranuclear palsy, a devastating tauopathy with almost no treatment options, and the 2012 primary cognitive endpoint came back negative. The development program was shuttered. That’s not a single-lab anecdote gone sideways; thats a well-resourced Phase 2/3 effort that produced a definitive answer for the PSP indication. Researchers need to hold that fact in one hand before they do anything else with this compound.

The underlying biology is a different story, and it’s genuinely worth knowing. Davunetide is an eight-amino-acid fragment of ADNP, activity-dependent neuroprotective protein, which is a zinc-finger protein with a critical SIP box motif that interacts directly with microtubule-end binding proteins. The idea is that NAP stabilizes EB1/EB3-tubulin interactions and in doing so slows the hyperphosphorylation and aggregation of tau. That’s a plausible and fairly specific mechanism. Multiple labs, not just the originating Gozes group in Tel Aviv, have reproduced effects in rodent tauopathy models, including APP-PSEN1 mice and P301L transgenic lines. The preclinical corpus is solid enough to take seriously.

What we find interesting right now is the ADNP syndrome angle. ADNP haploinsufficiency causes a syndromic intellectual disability with autistic features, and the field has produced a handful of publications over the past three years examining whether NAP peptide can rescue ADNP-syndrome mouse phenotypes. The Gozes lab has continued publishing in this direction, and there are now independent replication attempts from other groups. It’s early, the N is tiny, and we haven’t seen a structured human signal, but the translational question is at least reformulated in a way that isn’t capped by the PSP failure.

As a bench tool, davunetide has real value for anyone studying microtubule dynamics in neurons, tau biology, or ADNP-interactome questions. The intranasal delivery pharmacokinetics are unusually well-characterized for a research peptide, partly because of the clinical program. Researchers have a reasonably solid CNS exposure profile to work from. Sourcing is more accessible than it was, and the peptide is structurally simple enough that vendor quality is easier to verify by HPLC than for larger fragments.

We dont think this belongs near the top of anyone’s list unless they’re specifically working the ADNP biology or designing tauopathy assays that need a reasonably specific microtubule-protective control. For those investigators, its genuinely useful. For everyone else, the failed pivotal trial is load-bearing information and the translational arrow is, at best, pointing sideways.

Novelty

48

Mechanism promise

52

In-category differentiation

38

Evidence quality

48

Translational signal

28

Research bench value

50

Rationale Davunetide scores modestly across the board because its development program ended on a clean negative result in a well-powered Phase 2/3 PSP trial (2012), crushing its translational signal even though the preclinical mechanistic work is real and multi-lab. What keeps it from falling further is the renewed relevance of ADNP biology through ADNP syndrome research and the compound’s continued utility as a probe for microtubule dynamics and tau pathology in preclinical models.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

ADNP-derived octapeptide

An eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) studied in tauopathies and PSP.

Abstract

Davunetide (NAP, AL-108; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; CAS 173308-60-2; molecular weight 824.94) is an octapeptide derived from activity-dependent neuroprotective protein (ADNP). The peptide preserves microtubule integrity and reduces tau pathology in animal models of tauopathy. Davunetide was developed by Allon Therapeutics and advanced through Phase 2/3 trials in progressive supranuclear palsy (PSP); the pivotal trial in 2012 was negative for the primary cognitive endpoint, ending the development program. The compound is administered intranasally (the primary route of delivery to CNS for the formulation used in trials). Research-grade doses are 5 to 30 mg intranasally per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-125Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bupropion

Plain-language summaryIntrigue 75 / 100

Bupropion, sold as Wellbutrin and Zyban, is an atypical antidepressant that inhibits dopamine and norepinephrine reuptake (an NDRI rather than an SSRI). Also FDA-approved for smoking cessation. Avoids the sexual side effects common to SSRIs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Mature FDA-approved NDRI with real bench utility but low novelty ceiling and aging mechanism

Bupropion sits in that uncomfortable middle zone for bench investigators. FDA-approved since 1985, mechanism fully characterized, metabolic pathway mapped to CYP2B6, clinical trial database enormous. By almost every dimension that bench scientists use to judge whether a compound deserves time, bupropion looks like a closed chapter. And mostly, it is.

The part that keeps it from dropping lower is the secondary pharmacology. The non-competitive nicotinic acetylcholine receptor antagonism, particularly at alpha-3-beta-4 and alpha-4-beta-2 subtypes, is a genuinely distinct action that single-mechanism NDRIs dont have. This is what drove its clinical utility in smoking cessation before varenicline arrived and demonstrated superior abstinence rates, and its also why pharmacology labs still reach for bupropion when they need to dissect nicotinic signaling from monoamine reuptake contributions in behavioral assays. Thats narrow bench value, but its real bench value.

The hydroxybupropion metabolite situation complicates clean in vitro work. The parent compound and its active metabolite have diverging receptor affinities and pharmacokinetic profiles, which means bupropion is messier as a probe than its reputation suggests. Investigators running acute monoamine studies often have to account for metabolite accumulation in a way that makes interpretation harder, not easier. We think this is underappreciated in the literature that treats bupropion as a simple NDRI tool.

Evidence quality is the strongest axis and also the most misleading one for library purposes. Multiple phase 3 RCTs, decades of post-market data, FDA approval across three indications including seasonal affective disorder. The Contrave combination (bupropion plus naltrexone) added a more recent layer of weight-loss data and raised some genuinely interesting questions about opioid-dopamine crosstalk in reward circuitry. But clinical approval history isnt the point of this library. A compound can have overwhelming clinical evidence and still be a poor research target, because all the interesting questions have already been answered.

Thats where bupropion lands. The mechanism is solved. The translational arrow is definitive. For a research program specifically interrogating CYP2B6-mediated oxidative metabolism, nicotinic receptor subtype pharmacology, or monoamine system dissection, bupropion is a legitimate tool to have. For anyone looking for a compound that opens new mechanistic questions in behavioral or metabolic neuroscience, honestly, theres not much here. The frontier moved on.

Novelty

18

Mechanism promise

42

In-category differentiation

50

Evidence quality

82

Translational signal

75

Research bench value

55

Rationale Bupropion scores well on evidence and translational signal because it’s a fully approved drug with four decades of RCT data, but novelty is structurally suppressed by its 1985 approval date and thoroughly characterized mechanism; the dual NDRI-plus-nicotinic-antagonist profile provides modest bench-tool value for monoamine and cholinergic dissection work, not enough to push into established-active territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Aminoketone NDRI / nicotinic antagonist

An aminoketone norepinephrine and dopamine reuptake inhibitor FDA-approved for depression (Wellbutrin) and smoking cessation (Zyban).

Abstract

Bupropion (Wellbutrin, Zyban; CAS 34911-55-2; molecular formula C13H18ClNO; molecular weight 239.74) is a unicyclic aminoketone developed by Burroughs Wellcome and approved by the FDA in 1985 for major depressive disorder, with subsequent approval for smoking cessation (1997) and seasonal affective disorder. Mechanism is selective inhibition of norepinephrine and dopamine reuptake (NDRI) plus non-competitive nicotinic acetylcholine receptor antagonism. The active metabolite hydroxybupropion contributes substantially to the antidepressant activity. Pharmacokinetics: parent half-life ~14 hours; CYP2B6 metabolism. Approved doses are 150 to 450 mg per day. Lowers seizure threshold; contraindicated in seizure disorders and bulimia.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-141Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Kava (Piper methysticum)

Plain-language summaryIntrigue 60 / 100

Kava (Piper methysticum) is a Pacific Island plant traditionally used for ceremonial and social purposes. The kavalactones produce GABAergic anxiolytic effects without the dependence of benzodiazepines. Hepatotoxicity is a documented concern with low-quality preparations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

A well-evidenced botanical anxiolytic with real human signal but little frontier research appeal

Look, kava is one of the more pharmacologically legitimate botanicals in the anxiety space. That’s not nothing. The kavalactone fraction has a genuinely multi-target profile: GABA-A positive modulation, voltage-gated sodium channel inhibition, and some dopaminergic activity, with yangonin carrying a CB1 partial agonist component that’s quietly interesting. For a plant extract, thats a reasonably specific and at least partially characterized mechanism. The Pittler and Ernst Cochrane review found statistically significant reductions in Hamilton Anxiety Rating Scale scores versus placebo across several trials, and the effect sizes, while modest, are real. In the botanical anxiolytic category, kava genuinely leads the field. Valerian, passionflower, lemon balm none of them have a comparable RCT base.

Here’s the thing though: none of that puts kava anywhere near the research frontier. The core mechanism story is decades old. GABA-A modulation is probably the most exhaustively studied pharmacological target in psychiatry, and adding sodium channel block and a hint of CB1 activity doesn’t elevate kava out of a very crowded space. A bench investigator looking to probe GABAergic biology has benzodiazepines, barbiturates, neurosteroids, and a half-dozen better-characterized positive modulators available. Kava isn’t the cleaner tool; its the botanically interesting tool, which is a different thing.

The hepatotoxicity signal complicates matters further. The cultivar and extraction story is real, noble cultivars processed in traditional water extraction appear substantially safer than ethanolic extracts of non-noble material, but the European bans and subsequent regulatory uncertainty have had a chilling effect on serious institutional research. German BfR, the UK, and Switzerland all moved against it at various points. That history makes it a hard compound to build a funded research program around, even though the mechanism itself isn’t particularly dangerous when the chemistry is controlled.

We think the most intellectually alive angle left in kava research is the cultivar-specific kavalactone profiling work: understanding how different noble versus tudei versus medicinal cultivar chemotypes produce different CNS pharmacology, and whether particular kavalactone ratios have meaningfully different receptor activity profiles. Yangonin’s CB1 affinity is also worth more attention than it’s gotten. But these are niche questions inside a mature area, not a new frontier. For most research programs in 2025, kava is a known quantity. Interesting history, real signal, modest effect sizes, and a regulatory headache. That adds up to a compound you understand rather than one you chase.

Novelty

22

Mechanism promise

38

In-category differentiation

38

Evidence quality

52

Translational signal

52

Research bench value

38

Rationale Kava has genuine multi-target pharmacology and one of the cleaner RCT bases among botanical compounds, but the core mechanism space (GABAergic anxiolytics, sodium channel blockers) is deeply saturated and the kavalactone story is decades old; the hepatotoxicity controversy has further chilled serious research investment, leaving the frontier appeal low despite respectable evidence quality.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pacific Island botanical / kavalactone source

A Pacific Island root containing kavalactones with anxiolytic, sedative, and muscle-relaxant activity through GABA-A modulation and other mechanisms.

Abstract

Kava (Piper methysticum) is a perennial shrub native to the Pacific Islands whose root has been used ceremonially and medicinally for centuries. The active constituents are kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin); the kavalactone profile varies among kava cultivars (the “noble” cultivars with kavain-dominant profiles being preferred for traditional use). Pharmacology includes GABA-A receptor modulation, voltage-gated sodium channel inhibition, and dopamine receptor effects. Hepatotoxicity has been reported with kava products, leading to bans in some European jurisdictions; the toxicity has been linked to particular cultivars or extraction methods rather than kava per se. Doses are typically 100 to 250 mg kavalactones per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-157Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 50 51 52 53 54 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.